229 related articles for article (PubMed ID: 2875791)
1. Intrasplenic administration of interleukin-2 to potentiate specific chemoimmunotherapy in tumor-bearing mice.
Nomi S; Naito K; Kahan BD; Pellis NR
Cancer Res; 1986 Nov; 46(11):5606-10. PubMed ID: 2875791
[TBL] [Abstract][Full Text] [Related]
2. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
Naito K; Pellis NR; Kahan BD
Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
[TBL] [Abstract][Full Text] [Related]
3. Specific chemoimmunotherapy in tumor-bearing mice with extracted antigen, cyclophosphamide, and intrasplenic administration of interleukin-2.
Kahan BD; Nomi S; Pellis NR
Cancer; 1986 Feb; 57(3):477-83. PubMed ID: 3484658
[TBL] [Abstract][Full Text] [Related]
4. Tumor-specific chemoimmunotherapy of murine fibrosarcoma using tumor-specific transplantation antigen, cyclophosphamide, and interleukin-2.
Naito K; Nomi S; Komichi H; Ueda Y; Yamagishi H; Oka T; Pellis NR; Kahan BD
Cancer Detect Prev; 1992; 16(5-6):321-7. PubMed ID: 1361881
[TBL] [Abstract][Full Text] [Related]
5. Retardation of postsurgical metastases with the use of extracted tumor-specific transplantation antigens and cyclophosphamide.
Nomi S; Pellis NR; Kahan BD
J Natl Cancer Inst; 1984 Oct; 73(4):943-50. PubMed ID: 6237215
[TBL] [Abstract][Full Text] [Related]
6. Continuous intrasplenic interleukin-2 combined with antigen-specific chemoimmunotherapy.
Naito K; Pellis NR; Kahan BD
Arch Surg; 1986 Dec; 121(12):1415-20. PubMed ID: 3491596
[TBL] [Abstract][Full Text] [Related]
7. Effects of concomitant and sinecomitant immunity on postsurgical metastasis in mice.
Nomi S; Naito K; Kahan BD; Pellis NR
Cancer Res; 1986 Dec; 46(12 Pt 1):6111-5. PubMed ID: 3779631
[TBL] [Abstract][Full Text] [Related]
8. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE
J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908
[TBL] [Abstract][Full Text] [Related]
9. Active specific immunotherapy with extracted tumor-specific transplantation antigen, cyclophosphamide, and adoptive transfer of tumor-specific cytotoxic T-cell clones.
Naito K; Pellis NR; Kahan BD
Cell Immunol; 1988 Jan; 111(1):216-34. PubMed ID: 3257414
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of a carcinogen-induced murine sarcoma with soluble tumor-specific transplantation antigens.
Kahan BD; Tanaka T; Pellis NR
J Natl Cancer Inst; 1980 Nov; 65(5):1001-4. PubMed ID: 6159495
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapeutic effects of partially purified tumor-specific transplantation antigens on pulmonary metastases of a 3-methylcholanthrene-induced sarcoma in mice: a preliminary report.
Tanaka T; Pellis NR; Kahan BD
J Natl Cancer Inst; 1982 Nov; 69(5):1121-6. PubMed ID: 6957656
[TBL] [Abstract][Full Text] [Related]
12. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2.
Mulé JJ; Yang JC; Afreniere RL; Shu SY; Rosenberg SA
J Immunol; 1987 Jul; 139(1):285-94. PubMed ID: 3108401
[TBL] [Abstract][Full Text] [Related]
13. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells.
Shu S; Rosenberg SA
J Immunol; 1985 Oct; 135(4):2895-903. PubMed ID: 2411817
[TBL] [Abstract][Full Text] [Related]
14. Cellular interactions and the role of interleukin 2 in the expression and induction of immunity against a syngeneic murine sarcoma.
Chou T; Shu S
J Immunol; 1987 Sep; 139(6):2103-9. PubMed ID: 2957448
[TBL] [Abstract][Full Text] [Related]
15. Therapy of advanced solid tumors in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells.
Kedar E; Ben-Aziz R; Shiloni E
Isr J Med Sci; 1988; 24(9-10):494-504. PubMed ID: 3264551
[TBL] [Abstract][Full Text] [Related]
16. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
Shu SY; Chou T; Rosenberg SA
J Immunol; 1987 Jul; 139(1):295-304. PubMed ID: 2953816
[TBL] [Abstract][Full Text] [Related]
17. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
18. Active specific chemoimmunotherapy of lymph-node metastasis from a poorly immunogenic murine fibrosarcoma.
Naito K; Oka T; Nomi S; Yamagishi H; Kahan BD
Jpn J Cancer Res; 1989 Nov; 80(11):1119-26. PubMed ID: 2514172
[TBL] [Abstract][Full Text] [Related]
19. The immunological basis of tumor rejection: the absolute dependence of the effector arm on sensitized T cells after chemoimmunotherapy of a murine sarcoma.
Evans R; Duffy T
J Immunol; 1985 Jun; 134(6):4255-60. PubMed ID: 3872913
[TBL] [Abstract][Full Text] [Related]
20. In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells.
Shu S; Chou T; Rosenberg SA
J Immunol; 1986 May; 136(10):3891-8. PubMed ID: 3486223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
